Characterization of mechanisms regulating multiciliated cell specification using patient-specific induced pluripotent stem cells.
使用患者特异性诱导多能干细胞来表征调节多纤毛细胞规范的机制。
基本信息
- 批准号:10608728
- 负责人:
- 金额:$ 50.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-03-15 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AddressAsthmaAttentionAutomobile DrivingBiological ModelsCRISPR/Cas technologyCell Differentiation processCellsChronic BronchitisCiliaClinicClone CellsClustered Regularly Interspaced Short Palindromic RepeatsCoiled-Coil DomainComplexCystic FibrosisDNA Sequence AlterationDependenceDevelopmentDiagnosisDiagnosticDiseaseElectronsEmbryoEpithelialEpithelial CellsEtiologyEvaluationFamilyFrequenciesFunctional disorderGMNN geneGene Expression ProfilingGenerationsGenesGeneticGenetic TranscriptionGenotypeGoalsHealthHumanImpairmentIn VitroInhalationInheritedKnock-inKnock-outLeadLungLung diseasesMethodsModelingMolecularMucociliary ClearanceMucous body substanceMutateMutationOrganellesPathologyPathway interactionsPatientsPb clearancePhenotypePostnatal respiratory distressPower strokePrimary Ciliary DyskinesiasProteinsRecurrenceReporterReproducibilityResearchRespiratory DiseaseRespiratory Tract InfectionsSignal PathwaySignal TransductionSkinStructural ProteinStructureSystemValidationXenopusairway epitheliumblastomere structurecausal variantchronic respiratory diseaseciliopathycilium biogenesiscilium motilitycomparativedifferentiation protocolexperimental studyfluid flowgene functiongenetic testinghuman modelimprovedin vitro Modelinduced pluripotent stem cellinnovationinsightknock-downlung developmentlung injurymutantnew therapeutic targetnotch proteinnovelnovel therapeuticsoverexpressionparticlepathogenpreventprogenitorprogramsstem cellstargeted treatmenttooltranscriptometranscriptome sequencing
项目摘要
PROJECT SUMMARY
Mucociliary clearance is an essential function to prevent chronic airway disease. In the healthy lung, multiple
motile cilia beat synchronously to transport inhaled particles and mucus out of the airways. Poor mucociliary
clearance arises when motile cilia function is impaired, and is a fundamental feature of many inherited and
acquired respiratory diseases, including primary ciliary dyskinesia (PCD), asthma, chronic bronchitis and cystic
fibrosis (CF). Since motile cilia are complex and highly specialized organelles, a large spectrum of genes,
many yet to be discovered, likely contribute to the various forms of PCD, where cilia may be absent, reduced in
number, or missing key structures that enable an effective, coordinated power stroke. This wide breadth of
pathologies makes diagnosis difficult, requiring highly specialized expertise for interpretation of electron
micrographs and ciliary beat frequency, and treatment is mainly symptomatic. Understanding the complexity of
ciliopathy-driven lung disease and development of targeted therapies for these disorders is hindered by a lack
of reproducible patient-specific in vitro models to study molecular mechanisms that govern human multiciliated
cell (MCC) specification and function. This experimental barrier is addressed in this application by exploiting
our novel, in vitro human system to systematically identify causative mutations and signaling mechanisms
underlying inherited and acquired forms of ciliary dysfunction. We are uniquely poised with our expertise in
ciliogenesis, gene editing (CRISPR/Cas9) and human iPSC to complete the following specific aims: (Aim 1)
Evaluate MCC differentiation from iPSCs and generate a complete human MCC transcriptome; (Aim 2)
Evaluate and correct ciliary dysfunction in lung epithelial cells derived from DNAH5 mutant PCD patient iPSC;
(Aim 3) Identify and evaluate novel defective cilia genotypes in PCD patients with no currently identified
causative genetic mutation. The expected overall impact of this innovative proposal is to gain mechanistic
understanding of human MCC specification and function using a robust in vitro model where a direct
comparison between control and PCD patient cells will lead to a better understanding of the known human
genes that lead to ciliary dysfunction. Moreover, this experimental approach will create a robust pipeline for
identification of novel mutations causative of PCD, thus providing significant new insights into mechanisms
underlying inherited and acquired diseases characterized by ciliary dysfunction. The proposed research is
innovative as we will exploit our human iPSC approach to determine key regulators of MCC differentiation.
Systematic comparison of human iPSC-derived MCC from PCD patients will lead to the functional validation of
known and novel causative mutations while addressing a critical need of a reproducible and defined human
model system in which to carry out these experiments. These studies should lead to the rapid progression of
novel therapeutics and better diagnostic/genetic tests for PCD to the clinic.
项目摘要
粘膜纤毛清除是预防慢性气道疾病的基本功能。在健康的肺中,
活动纤毛同步跳动,将吸入的颗粒和粘液输送出气道。黏膜纤毛不良
当运动纤毛功能受损时,清除就会出现,并且是许多遗传性和
获得性呼吸道疾病,包括原发性纤毛运动障碍(PCD)、哮喘、慢性支气管炎和囊性
纤维化(CF)。由于运动纤毛是复杂和高度专业化的细胞器,大量的基因,
许多尚未被发现的,可能有助于各种形式的PCD,其中纤毛可能缺失,减少,
数字,或失踪的关键结构,使一个有效的,协调的动力冲程。这片广阔的
病理学使得诊断困难,需要高度专业化的专业知识来解释电子
显微照片和纤毛跳动频率,治疗主要是对症。理解复杂性
纤毛疾病驱动的肺部疾病和这些疾病的靶向治疗的发展受到缺乏
可重复的患者特异性体外模型,以研究控制人类多纤毛的分子机制
电池(MCC)规格和功能。在本申请中,通过利用
我们的新的体外人类系统,系统地识别致病突变和信号传导机制
潜在的遗传性和获得性形式的睫状体功能障碍。我们凭借我们的专业知识,
纤毛发生、基因编辑(CRISPR/Cas9)和人iPSC以完成以下具体目标:
评估来自iPSC的MCC分化并生成完整的人MCC转录组;(目标2)
评估和纠正源自DNAH 5突变PCD患者iPSC的肺上皮细胞中的纤毛功能障碍;
(Aim 3)鉴定和评估PCD患者中的新的缺陷纤毛基因型,
致病基因突变这一创新提案的预期总体影响是获得机械性
使用稳健的体外模型了解人MCC的规格和功能,其中直接
对照和PCD患者细胞之间的比较将导致更好地理解已知的人类细胞,
导致纤毛功能障碍的基因此外,这种实验性的方法将创建一个强大的管道,
鉴定导致PCD的新突变,从而为机制提供重要的新见解
以纤毛功能障碍为特征的潜在遗传和获得性疾病。拟议的研究是
创新,因为我们将利用我们的人类iPSC方法来确定MCC分化的关键调节因子。
来自PCD患者的人iPSC衍生的MCC的系统性比较将导致以下的功能验证:
已知的和新的致病突变,同时解决了一个可重复的和定义的人的关键需要,
模型系统,在其中进行这些实验。这些研究应该会导致
新的治疗方法和更好的诊断/遗传测试PCD的临床。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Application of iPSC to Modelling of Respiratory Diseases.
- DOI:10.1007/5584_2019_430
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Calvert BA;Ryan Firth AL
- 通讯作者:Ryan Firth AL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Amy Leanne Ryan其他文献
Amy Leanne Ryan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Amy Leanne Ryan', 18)}}的其他基金
Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung Diseases
肺生物学和肺部疾病中的干细胞、细胞疗法和生物工程
- 批准号:
10753310 - 财政年份:2023
- 资助金额:
$ 50.14万 - 项目类别:
Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung Diseases
肺生物学和肺部疾病中的干细胞、细胞疗法和生物工程
- 批准号:
10318408 - 财政年份:2021
- 资助金额:
$ 50.14万 - 项目类别:
Characterization of mechanisms regulating multiciliated cell specification using patient-specific induced pluripotent stem cells.
使用患者特异性诱导多能干细胞来表征调节多纤毛细胞规范的机制。
- 批准号:
9889170 - 财政年份:2018
- 资助金额:
$ 50.14万 - 项目类别:
相似海外基金
Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
- 批准号:
2901112 - 财政年份:2024
- 资助金额:
$ 50.14万 - 项目类别:
Studentship
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
- 批准号:
485504 - 财政年份:2023
- 资助金额:
$ 50.14万 - 项目类别:
Salary Programs
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
- 批准号:
495593 - 财政年份:2023
- 资助金额:
$ 50.14万 - 项目类别:
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
- 批准号:
485322 - 财政年份:2023
- 资助金额:
$ 50.14万 - 项目类别:
Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
- 批准号:
493135 - 财政年份:2023
- 资助金额:
$ 50.14万 - 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
- 批准号:
493526 - 财政年份:2023
- 资助金额:
$ 50.14万 - 项目类别:
Operating Grants
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
- 批准号:
10659658 - 财政年份:2023
- 资助金额:
$ 50.14万 - 项目类别:
Treating Maternal Depression in an Urban Community-Based Pediatric Asthma Clinic: Targeting Maternal Mood, Child Asthma Outcomes, and Health Disparities
在城市社区小儿哮喘诊所治疗孕产妇抑郁症:针对孕产妇情绪、儿童哮喘结果和健康差异
- 批准号:
10723233 - 财政年份:2023
- 资助金额:
$ 50.14万 - 项目类别:
Improving Prediction of Asthma-related Outcomes with Genetic Ancestry-informed Lung Function Equations
利用遗传祖先信息的肺功能方程改善哮喘相关结果的预测
- 批准号:
10723861 - 财政年份:2023
- 资助金额:
$ 50.14万 - 项目类别:
Prenatal Fatty Acid Supplementation and Early Childhood Asthma and Atopy in Black American Families
美国黑人家庭产前脂肪酸补充剂与儿童早期哮喘和特应性
- 批准号:
10586398 - 财政年份:2023
- 资助金额:
$ 50.14万 - 项目类别: